Navegando por Assunto "Hemoglobinas glicadas"

Filtrar resultados informando as primeiras letras
Agora exibindo 1 - 1 de 1
  • Nenhuma Miniatura disponível
    Item
    Avaliação do impacto da utilização do sistema de infusão contínua de insulina na qualidade de vida de pacientes portadores de Diabetes Mellitus do tipo 1
    (Centro Universitário do Estado do Pará, 2023-05-30) Monteiro, Demmy Chaves Amaral; Chaves, Michelle Luiza da Silva; Santos, Flávia Marques; http://lattes.cnpq.br/8601394323526613; Rocha, Mônica Souza Filho Moura; http://lattes.cnpq.br/1302412321438738; Miranda, Nádia Costa de; http://lattes.cnpq.br/6968956833621813
    Type 1 Diabetes Mellitus (DM1) is a chronic autoimmune disease with a genetic determinant in which there is an absence or deficiency in the production of insulin, which regulates blood glucose and provides energy for the body. People with this disease are permanently dependent on exogenous insulin for homeostasis of glucose metabolism. The treatment to replenish insulin stocks is usually uncomfortable, presenting certain limitations to daily life. One way to minimize the negative impact of therapy and improve quality of life (QoL) is through the continuous insulin infusion system. To evaluate the quality of life with the use of the Continuous Insulin Infusion System in patients with Type 1 Diabetes Mellitus in the DM1 outpatient clinic of the Medical Specialties Center of CESUPA. Cross-sectional study that evaluates, through a modified questionnaire, the quality of life of 8 patients of both sexes, with DM1, in use of SICI for at least 6 months, accompanied at the Medical Specialties Center of CESUPA (CEMEC). Satisfaction with treatment assessed by part I of the questionnaire is high, with a value of 75% very satisfied and 25% satisfied. Of the analyzed subscales, “Impact on Social Life" is the one that presents the least satisfaction (62.5%) and “Well-being” is the one that presents the greatest satisfaction (100%). “decrease in the number of punctures” (37.5%) and “better glycemic control” (25%). In points of displeasure, “nothing” is reported in 37.5% of patients. 62.5% of patients had a total of 0 episodes of severe hypoglycemia in the last year, and 50% had an average decrease of 0.6-1 in HbA1c from the first year of pump placement compared to the year of the survey. Regarding quality of life, 75% of the patients obtained “Excellent” and 25% “Good” QoL, with a result of 120.6 ‡14.4. This study reveals a high QoL index for this sample of patients, ranging from “good” to “excellent”. The joint analysis of satisfaction with treatment and clinical data revealed that not only do patients have a positive perception of treatment in different areas of life, but also the positivity is proven by clinical data.